Use of sibutramine and other noradrenergic and
serotonergic drugs in the management of obesity
by
Ryan DH.
Pennington Biomedical Research Center,
Baton Rouge, LA, USA.
ryandh@pbrc.edu
Endocrine 2000 Oct;13(2):193-9

ABSTRACT

Drugs that act through noradrenergic and serotonergic mechanisms have historically served as the mainstays of pharmacologic treatments for obesity. This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets.

Fen/Phen
Serotonin
Fluoxetine
Sibutramine
Noradrenaline
Amphetamines
SSRIs and SNRIs
Sibutramine abuse
New slimming drugs
Sibutramine compared
Sibutramine and obesity
Sibutramine for binge-eaters
Sibutramine v dexfenfluramine
Sibutramine as an antidepressant
Sibutramine (Meridia): clinical use
Sibutramine (Meridia): clinical pharmacology
Dual-action antidepressants and slimming-drugs

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family